###begin article-title 0
Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 19 20 19 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 202 204 202 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Sialyl Lewis x (sLex) antigen is a carbohydrate antigen that is considered not only a marker for cancer but also implicated functionally in the malignant behaviour of cancer cells. Overexpression of sLex is associated with enhanced progression and metastases of many types of cancer including those of the mammary gland. Canine mammary tumours can invade and give rise to metastases via either lymphatic or blood vessels.
###end p 3
###begin p 4
E-Cadherin is specifically involved in epithelial cell-to-cell adhesion. In cancer, E-Cadherin underexpression is one of the alterations that characterizes the invasive phenotype and is considered an invasion/tumour suppressor gene. Partial or complete loss of E-Cadherin expression correlates with poor prognosis in canine malignant mammary cancer.
###end p 4
###begin p 5
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
The aim of this study was to analyse the sLex expression in canine malignant mammary tumours and to evaluate if the presence of sLex correlates with the expression of E-Cadherin and with clinicopathological features.
###end p 5
###begin title 6
Methods
###end title 6
###begin p 7
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 253 255 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 373 375 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Fifty-three cases of canine mammary carcinomas were analysed immunohistochemically using monoclonal antibodies against sLex (IgM) and E-Cadherin (IgG). The clinicopathological data were then assessed to determine whether there was a correlation with sLex tumour expression. Double labelled immunofluorescence staining was performed to analyse the combined expression of sLex and E-Cadherin.
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 312 314 312 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
sLex expression was consistently demonstrated in all cases of canine mammary carcinomas with different levels of expression. We found a significant relationship between the levels of sLex expression and the presence of lymph node metastases. We also demonstrated that when E-Cadherin expression was increased sLex was reduced and vice-versa. The combined analysis of both adhesion molecules revealed an inverse relationship.
###end p 9
###begin title 10
Conclusion
###end title 10
###begin p 11
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 250 252 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 404 406 404 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 506 511 <span type="species:ncbi:9606">woman</span>
In the present study we demonstrate the importance of sLex in the malignant phenotype of canine malignant mammary tumours. Our results support the use of sLex as a prognostic tumour marker in canine mammary carcinomas. Furthermore, we showed that sLex and E-Cadherin expression were inversely correlated. Future studies are warranted to clarify the molecular mechanism underlying the relation between sLex and E-Cadherin in canine mammary carcinoma cells which represents an important comparative model to woman breast cancer.
###end p 11
###begin title 12
Background
###end title 12
###begin p 13
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 61 65 <span type="species:ncbi:9615">dogs</span>
Mammary tumours are the most common tumours in intact female dogs and approximately 40% to 50% of these tumours are malignant [1]. All malignant canine mammary tumours have the potential to metastasise. In general canine malignant tumours metastasise via the lymphatics to the regional lymph nodes or hematogenously to the lungs that represent the most common site of distant metastases. [1-3]
###end p 13
###begin p 14
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Malignant transformation is associated with abnormal glycosylation, resulting in expression of altered carbohydrate determinants, such as the Sialyl Lewis x (sLex) antigen. Altered cell surface glycosylation is a prominent feature of malignant tumour cells and define their invasive and/or metastatic properties in general [4-12].
###end p 14
###begin p 15
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 655 656 655 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 665 667 665 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Tumour metastasis is a multistep process requiring detachment of malignant cells from the primary tumour, invasion of blood or lymph vessels, interaction with endothelium, extravasation at distant sites and formation of new tumour foci [9,12,13]. It is generally accepted that every step of the metastatic cascade is dependent on specific adhesive interactions of cancer cells with other cells and components of the extracellular matrix. These interactions are mediated by different families of adhesion molecules including cadherins, integrins, members of the immunoglobulin superfamily, and selectins and their carbohydrate ligands - Sialyl Lewis a (sLea) and sLex [9,13,14].
###end p 15
###begin p 16
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 336 338 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 339 341 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
sLex is a tetrasaccharide (NeuAcalpha2 --> 3Galbeta1 --> 4[Fucalpha1 --> 3]GlcNAcbeta1 --> R) that is particularly relevant from a biological standpoint. It is involved in selectin-mediated adhesion of cancer cells to vascular endothelium and this determinant is thought to be closely associated with hematogenous metastases of cancer [12-17]
###end p 16
###begin p 17
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 280 282 280 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 594 596 594 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 707 709 707 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 818 820 818 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 238 243 <span type="species:ncbi:9606">woman</span>
###xml 425 430 <span type="species:ncbi:9606">human</span>
In humans, the expression of sLex is significantly increased in carcinoma cells [4,7,18]. Many clinical studies have shown an association between the expression of sLex on tumours and enhanced tumour progression and metastasis [7,19]. In woman breast carcinoma the presence of sLex was also correlated with poor prognosis [20,21]. In fact, the presence of sLex has been used as a prognostic tumour marker in various types of human cancer [7,19], e.g. lung [22], bladder [8], breast [20,21,23], prostate [24], colon [25] and gastric [26-28] carcinoma. Little is known about the expression of sLex in canine tumours. To the best of our knowledge only the study of Nakagawa et al describe the expression of sLex in canine and feline mammary gland tumours [29], but no significant correlation between the expression of sLex and prognosis has been described in canine or feline tumours.
###end p 17
###begin p 18
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 297 302 <span type="species:ncbi:9606">woman</span>
sLex and E-cadherin are two adhesion molecules that seem to be involved in malignant progression with opposite roles [31]. Alpaugh et al have described a cooperative role between E-cadherin and sLex in the passive dissemination of tumour emboli and in the genesis of the lymphovascular embolus of woman's Inflammatory Breast Carcinoma [30-32].
###end p 18
###begin p 19
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 117 122 <span type="species:ncbi:9606">woman</span>
###xml 366 371 <span type="species:ncbi:9606">woman</span>
Recently, Jeschke et al identified a negative correlation between Sialyl Lewis antigens and E-cadherin expression in woman breast cancer and their lymph node metastases [23]. This combined analysis of tumour antigens involved in adhesion of breast cancer cells has never been described in canine mammary tumours, which constitutes an important comparative model for woman breast cancer.
###end p 19
###begin p 20
###xml 127 129 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 209 211 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
The purpose of the present study is to analyse, by immunohistochemical staining methods, the expression of the carbohydrate sLex in canine malignant mammary tumours and to evaluate the relationship between sLex expression and tumour clinicopathological features. The relation between the expression of the molecules sLex and E-Cadherin [33] in canine malignant mammary tumours was also investigated.
###end p 20
###begin title 21
Methods
###end title 21
###begin title 22
Tissue specimens
###end title 22
###begin p 23
###xml 421 423 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 116 120 <span type="species:ncbi:9615">dogs</span>
Fifty-three malignant mammary tumours and 102 local and regional lymph nodes were surgically removed from 35 female dogs aged from 3 to 16 (mean, 9.9 years), of various pure or mixed breeds. The specimens were fixed in 10% neutral buffered formalin. After dehydration and paraffin wax embedment, sections of 4 mum were cut from each representative paraffin blocks for staining with haematoxylin and eosin (HE) and for sLex and E-cadherin immunohistochemistry (IHC).
###end p 23
###begin p 24
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
Lymph nodes were classified according to the presence of cancer cells (positive or negative), using HE and cytokeratin IHC methods [33].
###end p 24
###begin title 25
Histological examination of the tumours
###end title 25
###begin p 26
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Tumours, including benign proliferative lesions found in the vicinity of the tumours, were classified independently by two observers from HE-stained sections on the basis of the diagnostic criteria of the World Health Organization classification of tumours in domestic animals [34].
###end p 26
###begin p 27
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
The presence of intra-tumoral necrosis was registered for each case and evaluation and classification of the mode of tumour growth was assessed as previously described [33].
###end p 27
###begin title 28
Follow-up data
###end title 28
###begin p 29
###xml 221 225 <span type="species:ncbi:9615">dogs</span>
###xml 303 307 <span type="species:ncbi:9615">dogs</span>
All animals were clinically evaluated every 3 months (by physical examination, thoracic radiography and abdominal ultrasound) for the presence of distant metastases during a follow-up period of 2 years after surgery. All dogs were followed until death or until the end of the observation period. In all dogs that died with suspected distant metastases, complete necropsies were performed and histological confirmation was obtained.
###end p 29
###begin title 30
Immunohistochemistry
###end title 30
###begin p 31
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Canine mammary cancer tissues, which had been resected by the curative operation were routinely processed and used for immunostaining of sLex and E-cadherin.
###end p 31
###begin p 32
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 183 185 183 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
Immunostaining was performed by the modified avidin-biotin-peroxidase complex (ABC) method [35]. Two distinct monoclonal antibodies (mAbs) were used: the mAb FH6 generated against sLex epitope [36] and the monoclonal mouse anti-human E-cadherin antibody (clone 4A2C7, Zymed, S.Francisco, California, USA) [33].
###end p 32
###begin p 33
###xml 855 857 855 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 659 665 <span type="species:ncbi:9986">rabbit</span>
###xml 712 718 <span type="species:ncbi:9913">bovine</span>
###xml 1041 1047 <span type="species:ncbi:9986">rabbit</span>
###xml 1053 1058 <span type="species:ncbi:10090">mouse</span>
Tumour sections (4 um thick) were deparaffinized in xylene, dehydrated through graded concentrations of ethanol and washed with distilled water. Sections were then treated with Citrate buffer (sodium citrate antigen retrieval solution; 10 mM citric acid, pH = 6) for 20 minutes in a microwave oven at 600 W. The slides were cooled for 10 minutes at room temperature and rinsed twice in Phosphate buffered saline (PBS) for 5 minutes. Endogenous peroxidase activity was blocked by treating the section with hydrogen peroxide 3% in methanol for 10 min. After washing the slides in PBS, non-specific staining was eliminated by incubating the sections with normal rabbit serum (Dako) diluted at 1:5 in PBS containing bovine serum albumin (BSA) 10%, in a humid chamber for 20 min at room temperature. Excess normal serum was removed and replaced by the anti-sLex mAb FH6 diluted at 1:5. After overnight incubation (congruent with18 hours) at 4degreesC, slides were washed with PBS and incubated for 30 min with a 1:200 dilution of biotin-labelled rabbit anti-mouse secondary antibody (Dako). Sections were then washed with PBS and incubated for 30 min with avidin-biotin complex (Dako) diluted at 1:100. This was followed by staining the sections for 5 to 7 minutes with 0.05% 3,3 diaminobenzidinetetrahydrochloride (DAB) freshly prepared in 0.05 M Tris/hydroxymethylaminomethane buffer, pH 7.6, containing 0.1% hydrogen peroxide. Finally, sections were lightly counterstained with haematoxylin, dehydrated, and mounted.
###end p 33
###begin p 34
Dilution of primary antibody, biotin-labelled secondary antibody, and avidin-biotin complex were made with PBS containing 5% BSA.
###end p 34
###begin p 35
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 55 60 <span type="species:ncbi:9606">human</span>
All series included, as positive control sections of a human mixed gastric carcinoma previously shown to display prominent expression of sLex.
###end p 35
###begin p 36
Negative controls were performed by substitution of the primary antibody with immunoglobulins of the same subclass and concentration as the monoclonal antibody.
###end p 36
###begin title 37
Scoring of immunostaining and statistical analysis
###end title 37
###begin p 38
###xml 188 196 <span type="species:ncbi:9606">patients</span>
The degree of mAb FH6 reactivity with individual tissue sections was scored by percentage of stained carcinoma cells in the section by three authors (S.S.P., C.A.R., F.G.) without knowing patients outcome and clinicopathological features of the case. In the event of disagreement, slides were reviewed by the observers, and a consensus was obtained.
###end p 38
###begin p 39
###xml 17 19 17 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 35 37 35 37 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 109 117 109 117 <underline xmlns:xlink="http://www.w3.org/1999/xlink">negative</underline>
###xml 177 190 177 190 <underline xmlns:xlink="http://www.w3.org/1999/xlink">less than 25%</underline>
###xml 216 222 216 222 <underline xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;50%</underline>
###xml 264 270 264 270 <underline xmlns:xlink="http://www.w3.org/1999/xlink">50&#8211;75%</underline>
###xml 300 313 300 313 <underline xmlns:xlink="http://www.w3.org/1999/xlink">more than 75%</underline>
Expression of sLex and E-cadherin [33] in canine mammary carcinomas were classified in the following manner: negative, no immunoreactivity or immunostaining in very rare cells; less than 25% of cancer cells stained; 25-50%, well defined areas with positive cells; 50-75% of cancer cells stained; and more than 75% stained cells. Scoring of immunoreactivity was evaluated irrespectively of localization of positive cells and intensity of the staining.
###end p 39
###begin p 40
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
For statistical analysis the expression of sLex was regrouped in two percentual categories (<25% and >/=25%) in order to increase the number of cases in each category and in this manner improve the statistical power of the tests.
###end p 40
###begin p 41
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
The statistical relationship among variables was analysed using tables of frequencies and their significance tested by the Fisher's exact test [37]. P values less than 0.05 were considered a significant association.
###end p 41
###begin title 42
Double-labelling Immunofluorescence
###end title 42
###begin p 43
###xml 37 39 37 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 262 264 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
For simultaneous visualization of sLex and E-cadherin on the same tissue section, double-label immunofluorescence was performed. We chose the following representative tissue sections: sections with <25% sLex and >75% E-Cadherin expression; sections with >75% sLex and <25% E-Cadherin expression and sections with the same percentage of positive cells for both mAbs.
###end p 43
###begin p 44
###xml 325 331 <span type="species:ncbi:9986">rabbit</span>
###xml 385 391 <span type="species:ncbi:9913">bovine</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
###xml 658 664 <span type="species:ncbi:9986">rabbit</span>
###xml 670 675 <span type="species:ncbi:10090">mouse</span>
###xml 827 831 <span type="species:ncbi:9925">goat</span>
###xml 920 925 <span type="species:ncbi:10090">mouse</span>
###xml 1061 1065 <span type="species:ncbi:9925">goat</span>
###xml 1071 1076 <span type="species:ncbi:10090">mouse</span>
Paraffin sections were dewaxed, rehydrated and then treated with Extran (Merck, Frankfurt, Germany) 0.05% in distilled water for 10 min in a microwave oven at 750 W. After cooled for 20 min at room temperature, slides were rinsed twice in Phosphate-buffered saline (PBS) and then incubated for 20 min in a humid chamber with rabbit non-immune serum at a dilution 1:5 in PBS containing bovine serum albumin (BSA) 10%. Sections were incubated with the first primary mAb, anti-human E-Cadherin (clone 36, BD Biosciences Pharmigen, diluted 1:100 in PBS), overnight at 4degreesC. After washing twice for 5 min in PBS, sections were incubated with FITC-conjugated rabbit anti-mouse immunoglobulin (code F261; Dako, Glostrup, Denmark; diluted 1:100 in PBS). Sections were washed two times for 5 min in PBS and blocked with non-immune goat serum diluted 1:5 in PBS containing BSA 10%. Sections were then incubated with mAb FH6 (mouse IgM) diluted at 1:5, overnight at 4degreesC. Sections were washed two times for 5 min with PBS and incubated with Texas red-conjugated goat anti-mouse IgM (Jackson Immunoresearch) diluted 1:50 in PBS. Sections were washed as before and nuclei were counterstained with 4'-6-Diamidino-2-phenylindole (DAPI, Sigma) for 15 min in the dark, diluted at 1:100 in PBS. Sections were washed two times for 5 min in PBS and mounted with Vectashield (Vector Laboratories, Burlingame, USA).
###end p 44
###begin p 45
Dilutions of primary antibodies, secondary antibodies, and DAPI were made with PBS containing 5% BSA.
###end p 45
###begin title 46
Microscopy and image processing
###end title 46
###begin p 47
###xml 372 375 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Immunostained slides were examined under a fluorescence microscope (Leica DMIRE2) equipped with appropriate filters. Separate images for DAPI, Texas-Red and FITC staining were captured digitally at x200 and x400 magnification. The red (for Texas-Red), blue (for DAPI), and green (for FITC) components were merged and composite images were imported into Adobe Photoshop 7.0(R).
###end p 47
###begin title 48
Results
###end title 48
###begin title 49
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Clinical and pathological features of mammary carcinoma patients
###end title 49
###begin p 50
###xml 189 197 189 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 4 8 <span type="species:ncbi:9615">dogs</span>
All dogs that were included in this study were female. The mean age at surgery was 9.9 years old (range: 3-16 years old). Histological diagnosis of canine mammary carcinomas consisted of 2 in situ carcinomas, 13 complex carcinomas, 13 tubulopappilary carcinomas, 9 solid carcinomas, 1 spindle cell carcinoma, 3 mucinous carcinomas, 10 carcinosarcomas and 2 carcinomas in benign tumour.
###end p 50
###begin p 51
The mode of tumour growth was assessed in all of 53 tumours. Invasive tumours were more prevalent (28 cases, 52.8%) followed by expansive tumours (17 cases, 32.1%) and tumours with vessel invasion (8 cases, 15.1%).
###end p 51
###begin p 52
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
Lymph node metastases were evaluated in 50 tumours (in 3 cases the regional lymph nodes were not submitted). The majority of the cases did not show lymph node metastases (39, 78.0%) whereas eleven patients (22.0%) revealed metastases in regional lymph nodes. The majority of the cases that showed lymph node metastases were classified as carcinosarcomas (6 out of 11). The others were classified as complex carcinoma, tubulopapillary carcinoma and solid carcinoma. From the eleven cases that revealed nodal metastases, 4 patients revealed in addition, distant metastases. Seven patients with lymph node metastases died (in 4 animals was performed euthanasia because of the tumour and 3 animals died of other causes).
###end p 52
###begin p 53
The presence of intra-tumoral necrosis was observed in thirty tumours (56.6%), whereas 23 (43.4%) tumours did not show this feature.
###end p 53
###begin p 54
###xml 10 14 <span type="species:ncbi:9615">dogs</span>
###xml 91 95 <span type="species:ncbi:9615">dogs</span>
###xml 146 150 <span type="species:ncbi:9615">dogs</span>
Of the 35 dogs that were included in this study, 33 completed the follow-up period and ten dogs (30.3%) developed distant metastases. From the 17 dogs that died at the end of the follow-up period, 52,9% died because of the mammary carcinoma and 47,0% died from other causes.
###end p 54
###begin title 55
Expression of Sialyl Lewis x in canine mammary carcinomas
###end title 55
###begin p 56
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 144 146 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 206 208 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 274 276 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 354 362 354 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 757 758 757 758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 937 939 937 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
All of the carcinomas studied by immunohistochemistry showed expression of sLex antigen (Figure 1). Thirty two (60.4%) were found to express sLex in less than 25% of the cells, whereas 21 (39.6%) showed sLex expression in more than 25% of the cells. This distribution of sLex expression include the early stage cases of canine mammary carcinomas such as in situ carcinoma and carcinoma in benign tumour (Table 1). The staining was observed in the cytoplasm and/or in the cell membrane of epithelial cells. In tumour areas with cellular squamous differentiation, sLex was always expressed (Figure 2). In all cases, the adjacent normal mammary gland tissue and the adjacent benign proliferative lesions were evaluated and they did not showed expression of sLex. It was analysed a total of 43 adjacent benign proliferative lesions (6 simple adenomas, 8 epithelioses and the others were hyperplasias in general). In proliferative lesions sLex was expressed only in mammary gland secretion.
###end p 56
###begin p 57
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemical study of the expression of Sialyl Lewis x in canine malignant mammary tumours</bold>
###xml 130 132 130 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Immunohistochemical study of the expression of Sialyl Lewis x in canine malignant mammary tumours. A. Solid carcinoma; >75% of sLex expression; x400 B. Carcinosarcoma; 25-50% of cells stained; x400.
###end p 57
###begin p 58
Relationship between Sialyl Lewis x expression and clinicopathological features in canine malignant mammary tumours.
###end p 58
###begin p 59
* No lymph nodes were submitted with 3 tumours
###end p 59
###begin p 60
NS - Not significant (P > 0.05)
###end p 60
###begin p 61
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemical expression of Sialyl Lewis x in squamous metaplasia</bold>
Immunohistochemical expression of Sialyl Lewis x in squamous metaplasia. All cells that exhibit squamous metaplasia (arrows) are positive for Sialyl Lewis x. x400
###end p 61
###begin title 62
Relationship between Sialyl Lewis x expression and clinicopathological features
###end title 62
###begin p 63
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Table 1 summarizes the expression of sLex according to clinicopathological features.
###end p 63
###begin p 64
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
No significant relationship was found between the expression of sLex antigen and the different histological types of canine mammary carcinoma according to the World Health Organization classification of tumours in domestic animals [34].
###end p 64
###begin p 65
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Similarly, no significant relationship was observed between sLex expression and the growth pattern of mammary carcinomas.
###end p 65
###begin p 66
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 211 213 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
A total of 63.6% of tumours with lymph node metastases showed significantly higher sLex expression (>/=25%), whereas most (74.4%) of the tumours without lymph node metastasis showed underexpression (<25%) of sLex (p = 0.034).
###end p 66
###begin p 67
###xml 125 127 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Although this association did not reach a statistical significance, we observed that tumours without necrosis showed less sLex expression than tumours with necrosis (p = 0.07).
###end p 67
###begin p 68
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
No significant relationship was found between the expression of sLex antigen and distant metastases.
###end p 68
###begin title 69
Relationship between Sialyl Lewis x and E-cadherin expression
###end title 69
###begin p 70
###xml 33 35 33 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 322 324 322 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 499 501 497 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 584 586 582 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 655 656 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The analysis of expression of sLex and E-cadherin disclosed an inverse correlation among the two molecules, higher sLex expression was accompanied with lower E-cadherin expression and vice-versa (Figure 3). When mammary carcinomas show underexpression of E-cadherin (<25%), all of them simultaneously revealed a higher sLex expression (>/=25%). On the other hand when tumour samples showed overexpression of E-cadherin (>75%) the majority of them (93.1%) simultaneously revealed less than 50% of sLex expression. In summary, we found a significant relationship (p = 0.013) between sLex and E-cadherin expression in canine malignant mammary tumours (Table 2).
###end p 70
###begin p 71
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relation between Sialyl Lewis x and E-cadherin expression. </bold>
###xml 118 120 118 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 244 246 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Relation between Sialyl Lewis x and E-cadherin expression. The figure illustrates the negative correlation between sLex and E-Cadherin expression in canine malignant mammary tumours. When expression of E-cadherin increase, the expression of sLex decrease and vice-versa.
###end p 71
###begin p 72
Relationship between Sialyl Lewis x and E-cadherin expression in canine malignant mammary tumours.
###end p 72
###begin p 73
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 257 259 257 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
Simultaneous expression of sLex and E-cadherin was analysed using double-label immunofluorescence method (Figure 4), demonstrating the absence of overlapping between the two molecules (Figure 4). Based on these results, it seems that, when cells express sLex they do not express E-cadherin, and on the other hand when they are positive for E-cadherin they are negative for sLex.
###end p 73
###begin p 74
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Double-label immunofluorescence of canine malignant mammary tumour (Complex carcinoma)</bold>
###xml 233 235 233 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Double-label immunofluorescence of canine malignant mammary tumour (Complex carcinoma). A - Cells that are positive for Sialyl Lewis x (red) are negative for E-cadherin (green) and vice-versa. x200 B - Absence of co-expression of sLex and E-cadherin in the same cells. x400
###end p 74
###begin title 75
Discussion
###end title 75
###begin p 76
###xml 176 178 176 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 185 187 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Malignant transformation of tumour cells is associated with abnormal glycosylation, resulting in expression of altered carbohydrate determinants including the expression of sLex and sLea antigens [4,9,12]. These carbohydrate antigens have been shown to be useful tumour markers in carcinomas of different organs [4,9,12]. The biosynthesis of these oligosaccharides are usually increased and altered during the acquisition of the malignant phenotype and tumour progression [5,12]. Some studies refer that aberrant glycosylation is a result of initial oncogenic transformation, as well as a key event in induction of invasion and metastases [10,12].
###end p 76
###begin p 77
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 5 10 <span type="species:ncbi:9606">human</span>
Most human carcinomas show changes within cell surface carbohydrates compared to their normal counterparts [4,12].
###end p 77
###begin p 78
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 213 215 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 741 743 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 933 935 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1039 1041 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1106 1107 1106 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1182 1184 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1208 1210 1208 1210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 967 972 <span type="species:ncbi:9606">human</span>
sLex, present on the surface of tumour cells has been found to serve as ligands for endothelial E-selectin and was shown to play a major role in the process of adhesion of cancer cells to the endothelium [38]. sLex not only is a marker for cancer but also is functionally implicated in the malignant behaviour of cancer cells [4,12-14]. E-selectin, one of the selectin family member is expressed on the vascular endothelial cells and adheres to a carbohydrate ligand, sLex [15,16]. Binding of sLex, present on the cell membrane of neutrophil granulocytes, to E-selectin, expressed on activated endothelial cells, was shown to initiate neutrophil extravasation and migration into tissues [15]. It has been hypothesized that the E-selectin/sLex interaction can mediate the sequence of adhesion of tumour cells to endothelium and their subsequent extravasation in a process that mimics the above process of inflammation [15,17]. The sLex antigen is expressed by various human carcinomas such as: gastric carcinoma [26], colorectal carcinoma [25], lung cancer [22], prostate carcinoma [24], bladder carcinoma [8], oral [39], head&neck squamous cell carcinoma [40] and breast cancer [11,20,23]. The amounts of sLex expression are closely associated with progression and with poor prognosis in those cancers.
###end p 78
###begin p 79
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
In canine cancers, Nakagawa et al has described the expression of sLex in canine and feline mammary gland tumours. However no association with clinicopathological features and prognosis was observed [29,41].
###end p 79
###begin p 80
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 355 356 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
###xml 406 408 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
The present study demonstrates that in malignant canine mammary tumours the malignant transformation of the mammary gland is accompanied by expression of sLex. These results are in agreement with previous observations showing that in squamous metaplasia, used as criteria of malignancy in canine mammary cancer [42-44], there is a strong expression of sLexantigen. These observations support the use of sLex as a prognostic tumour marker in canine mammary carcinomas.
###end p 80
###begin p 81
###xml 63 65 63 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 394 396 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 320 325 <span type="species:ncbi:9606">woman</span>
In this study, we found no significant relationship between sLex expression and the histological type of the tumours, classified according to World Health Organization classification. This result is in agreement with the results described by Nakagawa et al in canine and feline mammary gland tumours [29]. Similarly, in woman breast cancer, Nakagoe et al did not find an association between sLex expression and histological type of the carcinoma [20].
###end p 81
###begin p 82
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 341 343 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 444 446 444 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 37 42 <span type="species:ncbi:9606">woman</span>
Previous studies have shown that, in woman breast cancer, tumour necrosis is associated with poorer survival [45-47] and higher recurrence rates [46]. In canine mammary tumours, the presence of large areas of necrosis within the tumour mass could be used as criteria for a diagnosis of malignancy [44]. In spite of no association between sLex expression and tumour necrosis we observed that some tumours with necrosis showed high amounts of sLex expression.
###end p 82
###begin p 83
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 348 350 348 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 475 477 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 593 595 593 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 747 749 747 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 412 417 <span type="species:ncbi:9606">woman</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 678 683 <span type="species:ncbi:9606">woman</span>
It is clear that the expression of sLex in tumours is a marker of the invasive and/or metastatic properties of the tumours [4,11]. In addition, it has been shown that sLex promotes binding of tumour cells at an invasion focus to endothelial cells through E-Selectin [11]. Many clinical studies show a clear association between the expression of sLex and tumours with enhanced progression and metastases [19]. In woman breast cancer, it was reported that the expression of sLex antigen in tumour cells was associated with poorer prognosis [20]. Matsuura et al demonstrated that the level of sLex was elevated in the sera of patients with metastatic breast cancers [21]. Still in woman breast cancer, Jeschke et al reports that overexpression of sLex was associated with poorer prognosis and malignant relapse [23].
###end p 83
###begin p 84
###xml 30 32 30 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
To date, the expression of sLex in canine malignant mammary tumours, was not correlated neither with clinicopathological features, neither with prognoses [29].
###end p 84
###begin p 85
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 265 267 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 430 432 430 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 549 551 549 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 668 670 668 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
In the present study we found a significant correlation between sLex expression and lymph node metastases. To the best of our knowledge, this is the first study to show such a relationship in canine malignant mammary tumours. These observations may suggest that sLex expression may also play a role in the process of local lymphatic invasion and metastization [38]. On the other hand, we did not observe an association between sLex expression and the development of distant metastases. This observation may suggest that in canine mammary tumours sLex does not contribute to haematogenous metastasis. However we could not rule out that the absence of association of sLex and haematogenous metastasis stems from the small number of cases studied for this clinicopathological feature.
###end p 85
###begin p 86
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 135 137 135 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
These combined results from the relation between sLex expression and the clinicopathological features allow us to conclude that the sLex carbohydrate structure contributes for the malignant phenotype and tumour progression of canine malignant mammary tumours.
###end p 86
###begin p 87
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 696 698 696 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 863 865 863 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1006 1008 1006 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1055 1057 1055 1057 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1215 1217 1215 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1344 1346 1344 1346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1465 1467 1465 1467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1727 1729 1727 1729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 1798 1800 1798 1800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1801 1803 1801 1803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2126 2128 2126 2128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1600 1605 <span type="species:ncbi:9606">woman</span>
Tumour cell dissemination and development of metastases is a multistep process involving complex interaction between cancer cells, extracellular matrix, the vascular system, the immune system and the target organs [48]. Adhesion molecules are contributory factors toward metastatic activity. Adhesion can be divided into reduced adhesion of tumour cell, tumour cell interaction and increased adhesion of floating tumour cells to vascular endothelial cells [48]. Recently we and other authors have described that the loss of E-Cadherin expression may have prognostic value in canine malignant mammary tumours [33,49]. In the present study, our results also showed that increasing expression of sLex correlates with lymph node metastases in canine mammary carcinomas. To address a possible cooperative role between these two molecules involved in cell adhesion, sLex and E-cadherin, we have compared their expression in canine malignant mammary tumours. Our results showed an inverse relationship between sLex and E-cadherin expression. Cases expressing sLex showed decrease E-Cadherin expression and vice-versa. Similarly, we could observe in doubled labelled immunofluorescence images, that cells that expressed sLex were negative for E-cadherin and vice-versa. This observation is the first indication of a significant relationship between sLex and E-cadherin expression in canine malignant mammary tumours. Based on our results it seems that the expression of sLex and/or E-cadherin on the same tumour cell could be regulated by an internal mechanism of the cell. In a previous study in a model of woman Inflammatory Breast Carcinoma (IBC), Alpaugh et al have described a cooperative role of E-cadherin overexpression and sLex underexpression in the genesis of the lymphovascular embolus of IBC [30,31]. These results showed that both types of adhesion molecules might play opposing roles within the same tumour cell model. Furthermore, Jeschke et al have also shown, in breast cancer, a negative correlation between the expression of Sialyl Lewis antigens and E-cadherin as the risk of breast cancer metastasis progresses [23].
###end p 87
###begin p 88
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 401 403 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Our findings, in canine mammary carcinomas, supports the generally accepted dogma that metastatic propensity is an active biologic process that includes the decrease of tumour cells adhesion at the primary tumour site (E-cadherin down-regulation) which is thought to be accompanied by higher mobility and invasiveness [50] contributing to the process of local lymphatic invasion and metastization (sLex overexpression).
###end p 88
###begin title 89
Conclusion
###end title 89
###begin p 90
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Our results demonstrate the importance of sLex in malignant phenotype of canine mammary carcinoma and support the use of sLex as a prognostic tumour marker in canine malignant mammary gland tumours.
###end p 90
###begin p 91
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 93 95 93 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
The significant relation between sLex and lymph node metastases allow us to conclude that sLex can be used as prognostic factor in canine malignant mammary tumours.
###end p 91
###begin p 92
###xml 85 87 85 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
There is an inverse relationship between the expression of the adhesion molecules sLex and E-cadherin, in canine mammary carcinomas.
###end p 92
###begin p 93
###xml 155 157 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 363 368 <span type="species:ncbi:9606">woman</span>
The present results warrants further investigation addressing the clarification of the molecular mechanism determining this inverse correlation between sLex and E-cadherin as well as the investigation of the mechanisms by which sLex interferes with homotypic cellular adhesion mediated by E-cadherin in canine malignant mammary tumours, as a comparative model to woman breast cancer.
###end p 93
###begin title 94
Abbreviations
###end title 94
###begin p 95
###xml 3 5 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 212 218 <span type="species:ncbi:9913">Bovine</span>
sLex = Sialyl Lewis x; sLea = Sialyl Lewis a; HE = Haematoxylin and eosin; IHC = Immunohistochemistry; ABC = Avidin-biotin-peroxidase-complex; mAbs = Monoclonal antibodies; PBS = Phosphate buffered saline; BSA = Bovine serum albumin; DAB = 3,3diaminobenzidinetetrahydrochloride; DAPI = 4'-6-Diamidino-2-phenylindole; NS = Non significant; IBC = Inflammatory Breast Carcinoma
###end p 95
###begin title 96
Competing interests
###end title 96
###begin p 97
The author(s) declare that they have no competing interests.
###end p 97
###begin title 98
Authors' contributions
###end title 98
###begin p 99
SSP and AJFM performed the study. SSP wrote the manuscript. CL participated in the immunohistochemistry method. NTM participated in the composition of the images. SSP and JC carried out the statistical analysis. CAR and FG participated in the design and coordination of the studies and contributed strongly to the revision of the manuscript. All the authors read and approved the final manuscript.
###end p 99
###begin title 100
Pre-publication history
###end title 100
###begin p 101
The pre-publication history for this paper can be accessed here:
###end p 101
###begin p 102

###end p 102
###begin title 103
Acknowledgements
###end title 103
###begin p 104
Supported by Portuguese agency " Fundacao para a Ciencia e a Tecnologia, Programa Operacional Ciencia e Inovacao 2010 (POCI 2010) do Quadro Comunitario de Apoio III" and Project grant no. POCI/CVT/57795/2004.
###end p 104
###begin p 105
SSP acknowledges FCT for financial support (SFRH/BD/21693/2005).
###end p 105
###begin article-title 106
Canine mammary gland tumors
###end article-title 106
###begin article-title 107
###xml 34 39 <span type="species:ncbi:9606">human</span>
A comparative study of canine and human breast cancer
###end article-title 107
###begin article-title 108
Prognostic factors in canine mammary tumors
###end article-title 108
###begin article-title 109
Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis
###end article-title 109
###begin article-title 110
Tumour malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism
###end article-title 110
###begin article-title 111
Synergistic effects of l- and p-selectin in facilitating tumour metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis
###end article-title 111
###begin article-title 112
Possible roles of tumour-associated carbohydrate antigens
###end article-title 112
###begin article-title 113
###xml 11 13 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Sialosyl-lex expression defines invasive and metastatic properties of bladder carcinoma
###end article-title 113
###begin article-title 114
Altered glycosylation in cancer: sialic acids and sialyltransferases
###end article-title 114
###begin article-title 115
Glycosylation defining cancer malignancy: new wine in an old bottle
###end article-title 115
###begin article-title 116
Glycosylation defining cancer cell motility and invasiveness
###end article-title 116
###begin article-title 117
Glycans in cancer and inflammation - potential for therapeutics and diagnostics
###end article-title 117
###begin article-title 118
###xml 86 91 <span type="species:ncbi:10090">mouse</span>
Deficiency in surface expression of e-selectin ligand promotes lung colonization in a mouse model of breast cancer
###end article-title 118
###begin article-title 119
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Sialyl lewisa: a tumour-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells
###end article-title 119
###begin article-title 120
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 79 80 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x</sup>
The discovery, biology, and drug development of sialyl lea and sialyl le and lex
###end article-title 120
###begin article-title 121
Selectin ligands
###end article-title 121
###begin article-title 122
###xml 71 76 <span type="species:ncbi:9606">human</span>
Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials
###end article-title 122
###begin article-title 123
Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited
###end article-title 123
###begin article-title 124
###xml 52 57 <span type="species:ncbi:9606">human</span>
Cell surface carbohydrates as prognostic markers in human carcinomas
###end article-title 124
###begin article-title 125
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Expression of abh/lewis-related antigens as prognostic factors in patients with breast cancer
###end article-title 125
###begin article-title 126
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases
###end article-title 126
###begin article-title 127
Sialyl lewis antigens: association with muc5ac protein and correlation with post-operative recurrence of non-small cell lung cancer
###end article-title 127
###begin article-title 128
###xml 147 154 147 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 76 81 <span type="species:ncbi:9606">human</span>
Expression of sialyl lewis x, sialyl lewis a, e-cadherin and cathepsin-d in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis
###end article-title 128
###begin article-title 129
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Up-regulation of the oligosaccharide Sialyl Lewisx : a new prognostic parameter in metastatic prostate cancer
###end article-title 129
###begin article-title 130
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Expression of Sialyl-Lex antigen defined by Mab AM-3 is an independent prognostic marker in colorectal carcinoma patients
###end article-title 130
###begin article-title 131
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 79 84 <span type="species:ncbi:9606">human</span>
Close correlation between increased sialyl-lewisx expression and metastasis in human gastric carcinoma
###end article-title 131
###begin article-title 132
###xml 17 19 17 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Dimeric Sialyl-Lex expression in gastric carcinoma correlates with venous invasion and poor outcome
###end article-title 132
###begin article-title 133
###xml 43 45 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
Clinicopathologic significance of sialyl Lex expression in advanced gastric carcinoma
###end article-title 133
###begin article-title 134
The expression of sialyl lewis x in canine and feline mammary gland tumors
###end article-title 134
###begin article-title 135
Cooperative role of e-cadherin and sialyl-lewis x/a-deficient muc1 in the passive dissemination of tumour emboli in inflammatory breast carcinoma
###end article-title 135
###begin article-title 136
###xml 28 32 28 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x/a </sup>
Relationship of sialyl-lewisx/a underexpression and e-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma
###end article-title 136
###begin article-title 137
Reversible model of spheroid formation allows for high efficiency of gene delivery ex vivo and accurate gene assessment in vivo
###end article-title 137
###begin article-title 138
E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables
###end article-title 138
###begin article-title 139
###xml 58 61 <span type="species:ncbi:9615">dog</span>
###xml 70 73 <span type="species:ncbi:9685">cat</span>
Histological classification of the mammary tumours of the dog and the cat
###end article-title 139
###begin article-title 140
A comparative study of the peroxidase-antiperoxidase method and the avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies
###end article-title 140
###begin article-title 141
###xml 142 144 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 155 157 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 160 162 160 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 166 167 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Novel fucolipids accumulating in human adenocarcinoma: III a hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3 NeuAcV3 III3 Fuc2 nLc 6)
###end article-title 141
###begin article-title 142
Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer
###end article-title 142
###begin article-title 143
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 53 55 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">x </sup>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
Immunohistochemical study of sialyl lea and sialyl lex antigen in oral squamous cell carcinoma: the association of sialyl lea expression with the metastatic potential
###end article-title 143
###begin article-title 144
Identification of sialyl lewis-x in squamous cell carcinoma of head and neck
###end article-title 144
###begin article-title 145
Cyclopedic protein expression analysis of cultured canine mammary gland adenocarcinoma cells from six tumours
###end article-title 145
###begin article-title 146
Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases
###end article-title 146
###begin article-title 147
Classification and behaviour of canine mammary epithelial neoplasms based on life-span observations in beagles
###end article-title 147
###begin article-title 148
The prognosis following the surgical excision of canine mammary neoplasms
###end article-title 148
###begin article-title 149
Simplified method of grading primary carcinomas of the breast
###end article-title 149
###begin article-title 150
###xml 171 179 <span type="species:ncbi:9606">patients</span>
Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients
###end article-title 150
###begin article-title 151
Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer
###end article-title 151
###begin article-title 152
Cancer invasion and metastasis: positive and negative regulatory elements
###end article-title 152
###begin article-title 153
E-Cadherin expression in canine mammary carcinomas with regional lymph node metastases
###end article-title 153
###begin article-title 154
Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness
###end article-title 154

